What caused the ANTH stock spike on 19 Mar 2026?

The spike to USD 0.0001 was driven by thin liquidity and a sudden volume increase to 4,050.00 shares on the PNK exchange, not a confirmed earnings or regulatory announcement. Microcap moves often reflect order-book dynamics.

What is Meyka AI's short-term ANTH stock forecast?

Meyka AI's model projects ANTH at USD 0.00026 in one year from the current USD 0.0001, implying roughly +158.01% upside. Forecasts are model-based projections and not guarantees.

Is ANTH stock a buy for long-term investors?

ANTH presents high risk due to negative EPS, low liquidity, and binary clinical outcomes. Meyka AI gives a B grade with a HOLD suggestion. Long-term investors should require positive trial or financing catalysts.

Where can I verify Anthera's company filings and pipeline details?

Check the company website and public filings for official updates and trial status. Official sources include the corporate site and broker-dealer listings such as OTC Markets for trade and disclosure details.

US Stocks

ANTH stock rises 9,900% on 19 Mar 2026 (PNK): risk-adjusted outlook and forecast

ByHuzaifa Zahoor March 19, 2026

ANTH stock grabbed attention on 19 Mar 2026 after Anthera Pharmaceuticals, Inc. (ANTH) on the PNK exchange traded at USD 0.0001, showing a 9,900.00% one-day move versus the prior close. The move came on light volume of 4,050.00 shares and follows thin trading and low liquidity that amplify intraday swings. Investors should view this gain in the context of Anthera’s small market cap of USD 2,618.00, a negative EPS of -0.01, and an ongoing clinical pipeline in Healthcare Biotechnology. Below we break down drivers, valuation, technicals, Meyka AI grading, and a model forecast to help frame risk and opportunity.